Document is current
Any future updates will be listed below
-
Authors
Sachpekidis, Christos http://orcid.org/0000-0001-8739-8741
Kopp-Schneider, Annette
Hassel, Jessica C.
Dimitrakopoulou-Strauss, Antonia
-
Funding
Funding for this research was provided by:
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 30 June 2021
Accepted: 1 September 2021
First Online: 8 September 2021
Declarations
:
: The presented results are part of the study entitled “Quantification of 18F-FDG kinetics with 4D PET-CT in patients with melanoma stage IV”, which was approved by the Ethical Committee of the University of Heidelberg (Ethikvotum: S-107 /2012—Ethical Committee 1 of the University of Heidelberg) and the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz; BfS: Z5-22463/2 2012-016). Informed consent was obtained from all individual participants included in the study.
: The given consent included also the consent for publication of anonymized data.
: Jessica C. Hassel<i>:</i> Advisory boards: MSD, Sunpharma, Pierre Fabre. Talks: BMS, MSD, Roche, Novartis, Almirall, Sanofi. Grant: BMS. Clinical trials: BMS, Roche, Novartis, Immunocore, BioNTech, 4SC, Merck, Genentech. All other authors declare no conflicts of interest.
